Today, the Cystic Fibrosis Foundation announced a new award of up to $2 million to Eloxx Pharmaceuticals Inc. to support the global Phase 2 clinical program of ELX-02, a potential therapy to treat people with cystic fibrosis who have nonsense mutations.
Site Search
Showing 1 - 4 of 4 results
Press Release
|
June 13, 2021
|
4 min read
Today, the Cystic Fibrosis Foundation announced that it has awarded up to $400,000 to Life Edit Therapeutics Inc. to explore the application of their unique gene editing technology in CF.
Press Release
|
Sept. 23, 2021
|
3 min read
New funding will support clinical development of two novel therapies to address complications of cystic fibrosis
Press Release
|
Sept. 10, 2021
|
3 min read
Today, the Cystic Fibrosis Foundation announced that it has awarded up to $2.17 million to Beyond Air® to support the development of a portable inhaled nitric oxide treatment for nontuberculous mycobacteria, difficult-to-treat bacteria that infect the lungs of people with cystic fibrosis.
Press Release
|
Feb. 16, 2021
|
4 min read